期刊文献+

尾加压素Ⅱ对自发性高血压大鼠胸主动脉的收缩效应及其对血管平滑肌细胞内ERK_(1/2)磷酸化的影响 被引量:4

Effects of urotensin Ⅱ on thoracic aorta of spontaneously hypertensive rats and on ERK_(1/2) phosphorylation in cultured vascular smooth muscle cells
下载PDF
导出
摘要 目的观察尾加压素Ⅱ(U-Ⅱ)对不同血压水平的自发性高血压大鼠(SHR)胸主动脉的收缩效应和U-Ⅱ对血管平滑肌细胞(VSMC)内ERK1/2和p38MAPK磷酸化的影响,以进一步明确U-Ⅱ对SHR的血管效应及其可能机制。方法离体血管灌流实验测定U-Ⅱ对胸主动脉张力的影响,采用免疫荧光标记UT受体在VSMC的表达,并通过蛋白质印迹的方法观察U-Ⅱ对VSMC内ERK1/2和p38MAPK磷酸化的作用。结果U-Ⅱ受体分布在VSMC上,累积浓度的U-Ⅱ对成年SHR去除内皮的胸主动脉环收缩效应明显强于WKY大鼠;在VSMC细胞内,U-Ⅱ可以浓度依赖性地激活VSMC内ERK1/2磷酸化,但对p38MAPK没有作用;ERK1/2阻断剂的应用不能阻断(肌凝蛋白轻链)MLC的磷酸化。结论U-Ⅱ对SHR离体血管表现出较强的收缩作用,可能通过ERK1/2及p38MAPK以外的其他通路参与了MLC的磷酸化以及VSMC的收缩效应。 Objective To observe the vasoconstrictor effect of urotensin Ⅱ (U- Ⅱ) on thoracic aorta of spontaneously hypertensive rats (SHR) and the effects of U- Ⅱ on ER1/,2 and p38 MAPK phosphorylation in cultured vascular smooth muscle cells (VSMC). Methods Isolated thoracic aorta organ bath study was used to observe the vasoconstrictor effect of U- Ⅱ. The phosphorylation levels of ERKV2 and p38MAPK were detected by Western blot. Results We observed that U-Ⅱ elicited a greater contractile response in endothelium-denuded thoracic aorta of SHR than that of the WKY rats. U -Ⅱ caused a dose-dependent ERK1/2 phosphorylation,which was blocked by ERK1/2 inhibitors. While the MLC phosphorylation was not prevented by ERK1/2 inhibitors. Conclusions ERK1/2 or p38MAPK was not the passageway through which U-Ⅱ was involved in the greater vasoconstriction in SHR.
出处 《复旦学报(医学版)》 CAS CSCD 北大核心 2008年第1期48-52,共5页 Fudan University Journal of Medical Sciences
基金 国家自然科学基金项目(30470628)
关键词 尾加压素Ⅱ 自发性高血压大鼠 胸主动脉 血管平滑肌细胞 ERK1/2 磷酸化 urotensin Ⅱ spontaneously hypertensive rats thoracic aorta vascular smooth muscle cell ERK1/2 phosphorylation
  • 相关文献

参考文献1

二级参考文献1

共引文献14

同被引文献33

  • 1张敬群,马业新,汪道文,肖建民.RNA干扰技术选择性下调大鼠血管紧张素Ⅱ 1a型受体及其作用的实验研究[J].中华心血管病杂志,2006,34(1):54-59. 被引量:12
  • 2Albertin G, Guidolin D, Sorato E, et al. Urotensin - II - stimulated expression of pro - angiogenic factors in human vascular endothelial cells [J]. Regul Pept,2011,172(1 -3) :16 -22.
  • 3Tsoukas P, Kane E, Giaid A. Potential Clinical Implications of the Urotensin II Receptor Antagonists [ J ]. Front Pharmacol, 2011,2 : 38.
  • 4Bai XY, Liu XC, Yang Q, et al. The interaction between human urotensin II and vasodilator agents in human internal mammary artery with possible clinical implications[J]. Ann Thorac Surg,2011,92(2) :610 -616.
  • 5Pawar R, Kemp W, Roberts S, et al. Urotensin II levels are an important marker for the severity of portal hypertension in children[ J]. J Pediatr Gastroenterol Nutr,2011,53 ( 1 ) : 88 - 92.
  • 6Liao Y, Du JB, Tang CS, et al. Change and significance in the levels of plasma urotensin II and catestatin in children with postural orthostatic tachycardia syndrome[J]. Beijing Da Xue Xue Bao,2011,43(3) :436 -439.
  • 7Cheung BM, Leung R, Man YB, et al. Plasma concentration of urotensin II is raised in hypertemion[ J]. J Hypertens ,2004,22(7) :1341 - 1344.
  • 8Chen Y, Chen H, Hoffmann A, et al. Adenovirus - mediated small - interference RNA for in vivo silencing of angiotensin ATla receptors in mouse brain [ J]. Hypertension ,2006,47 (2) :230 - 237.
  • 9Devereux RB,Alonsob K,Lutas EM,et al.Echocardiographic assessment of left ventricular hypertrophy comparision to necropsy findings[J].Am J Cordial,1986,57:450.
  • 10Ames RS,Sarau HM,Chambers JK,et al.Human urotensin-Ⅱ is a potent vadioconstrictor and agonist for the orphan receptor GPR14[J].Nature,1999,401 (6750):282-286.

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部